Sign in to view content

Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)

David M. Brown, MD

Video
Published 2020

Related

Suprachoroidal Delivery of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes
James C. Major, MD, PhD FACS FASRS
Annual Meeting Talks
2021
Post Hoc Analysis of Suprachoroidal CLS-TA Versus Real-World Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function
Steven Yeh, MD
Annual Meeting Talks
2021
Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more